Orient Securities Research Reports indicate that Marubi Biotechnology (603983.SH) is changing its company type and stock abbreviation to strengthen its biotechnology skincare positioning. The growth momentum is driven by a matrix of L products, new products, and sets. It is expected that the company will achieve sustained high revenue growth based on overall stable net margin. The leading L products will actively iterate and upgrade to drive growth; the four major products: eye cream, essence, mask, and face cream, along with three major sets, will be the core drivers for cosmetics. The optimization of product structure will lead to a steady rise in overall profitability, while continuing to advance its layout in the medical beauty Sector, with external investments and the establishment of a self-built R&D center. It is expected that the net profit attributable to the parent in 2025 will be 0.45 billion, corresponding to a PE of 29x, maintaining a "Strong Buy" rating.